Drugs / S1904
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07244406 | Jan 2025 → Mar 2027 expected | — | Hebei Senlang Biotechnology Inc., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S1904 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07244406 ↗ |
| Modality | Cell therapy | “Autologous CD19-targeting CAR T cells” NCT07244406 ↗ |
| Route | Intravenous | “intravenous injection once” NCT07244406 ↗ |
| Target | CD19 | “Autologous CD19-targeting CAR T cells” NCT07244406 ↗ |